Table 1 Patient characteristics

From: A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer

 

Cis/Doc ( n =43)

Ox/Doc ( n =45)

 

No. of patients

%

No. of patients

%

Total no. of patients

43

48.9

45

51.1

Age

Median

65

 

65

 

Range

47–86

 

39–82

 

Gender

Male

21

48.8

28

62.2

Female

22

51.2

17

37.8

ECOG

0–1

40

93.0

40

88.9

2

3

7.0

5

11.3

Histological subtype

Squamous cell

10

23.3

11

24.4

Adenocarcinoma

29

67.4

26

57.8

Other

4

9.3

8

17.8

Stage

IIIB

3

7.0

2

4.4

IV

40

93.0

43

95.6

Number of involved organs

⩽1

19

44.2

15

33.3

2

15

34.9

19

42.2

⩾3

9

20.9

11

24.4

Bevacizumab

7

16.3

8

17.8

  1. Abbreviations: Cis/Doc=cisplatin/docetaxel; Ox/Doc=oxaliplatin/docetaxel; ECOG=Eastern Cooperative Oncology Group.
Back to article page